Luis Sanchez-Perez

Duke Brain Tumor Immunotherapy Program, Duke University

Research Area

Biography

Luis Sanchez-Perez has not added Biography.
If you are Luis Sanchez-Perez and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 17	2015

Other Publications

Article	Year
A simple method to cure established tumors by inflammatory killing of normal cells. Nature biotechnology\| PubMed ID: 15300260	2004
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer research\| PubMed ID: 15753401	2005
Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 15843579	2005
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nature medicine\| PubMed ID: 16170322	2005
Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. Journal of immunology (Baltimore, Md. : 1950)\| PubMed ID: 16951382	2006
Delivery of CCL21 to metastatic disease improves the efficacy of adoptive T-cell therapy. Cancer research\| PubMed ID: 17210711	2007
Toll-like receptors in tumor immunotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17875756	2007
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer research\| PubMed ID: 18089828	2007
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB journal : official publication of the Federation of American Societies for Experimental Biology\| PubMed ID: 18587008	2008
Type 17 CD8+ T cells display enhanced antitumor immunity. Blood\| PubMed ID: 19471017	2009
Antitumor immunity can be uncoupled from autoimmunity following heat shock protein 70-mediated inflammatory killing of normal pancreas. Cancer research\| PubMed ID: 19738045	2009
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 19805141	2009
A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone\| PubMed ID: 20233612	2010
Research highlights. Immunotherapy\| PubMed ID: 20635909	2009
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer research\| PubMed ID: 20647327	2010
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. Journal of immunotherapy (Hagerstown, Md. : 1997)\| PubMed ID: 21499127	2011
Monoclonal antibody blockade of IL-2 receptor Î± during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood\| PubMed ID: 21768296	2011
Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity\| PubMed ID: 22177921	2011
Immunotherapy with tumor vaccines for the treatment of malignant gliomas. Current drug discovery technologies\| PubMed ID: 22339070	2012
Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 23248284	2013
Myeloablative temozolomide enhances CD8⁺ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PloS one\| PubMed ID: 23527092	2013
BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide. Cancer immunology, immunotherapy : CII\| PubMed ID: 23591978	2013
Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis. Journal of immunological methods\| PubMed ID: 23806556	2013
Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia\| PubMed ID: 24054399	2014
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24352643	2014
Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody. Oncoimmunology\| PubMed ID: 24475376	2013
Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody. Cancer immunology research\| PubMed ID: 24570975	2013
EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma. PloS one\| PubMed ID: 24722266	2014
Leveraging chemotherapy-induced lymphopenia to potentiate cancer immunotherapy. Oncoimmunology\| PubMed ID: 25610727	2014
Chimeric antigen receptor engineered T cells can eliminate brain tumors and initiate long-term protection against recurrence. Oncoimmunology\| PubMed ID: 25610729	2014